|
|
2635 Technology Forest Blvd. The Woodlands, TX 77381 USA phone:281-775-0600 fax:281-872-8585
|
|
| Symbol |
OPXA |
| Exchange |
NASDAQ |
| Founded |
2001 |
| Employees |
25 |
|
|
| www.opexatherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Develops treatments for autoimmune diseases. |
 |
| Management |
| Neil Warma, President and Chief Executive Officer; Jaye Thompson, Ph.D.,Senior-Vice President of Clinical Development and Regulatory Affairs; Don Healy Ph.D., Vice-President of Scientific Development and Manufacturing; Donna R. Rill, Senior Vice-President of Operations; John Ginzler, Vice-President of Finance; |
| |
|
|
|
|
|
|
|
| Keywords |
| Regenerative medicine, immunotherapy, multiple sclerosis, secondary progressive multiple sclerosis, inflammatory disease, MS |
|
|
|
|
|
|
| Description |
|
Opexa Therapeutics (Nasdaq: OPXA) is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS...
view more
|
 |
| Products / Services |
|
Opexa has recently rebranded its lead therapy with the new name, Tcelnaâ?¢. The product was previously known as Tovaxin. The rebranding of Tcelna encompasses the advancements made to the manufacturing...
view more
|
 |
| Technology / Differentiation |
| Tcelna is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPathâ?¢, Opexa's proprietary method for the production of a patient-sp...
view more
|
 |
| Market / Customers |
|
The company's product candidates have the potential to offer enhanced efficacy, safety and tolerability to address the significant unmet medical needs in several large patient populations.
Tcelna h...
view more
|
 |
| Status |
| Opexa's lead product, Tcelna(tm) (formerly Tovaxin(r)), is a novel T-cell immunotherapy positioned to enter Phase IIb clinical development for the treatment of patients with Secondary Progressive MS (...
view more
|
 |
|
|
|
|
|
|